Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O15554

UPID:
KCNN4_HUMAN

ALTERNATIVE NAMES:
IKCa1; KCa3.1; KCa4; Putative Gardos channel

ALTERNATIVE UPACC:
O15554; Q53XR4

BACKGROUND:
The Intermediate conductance calcium-activated potassium channel protein 4, known under aliases such as IKCa1, KCa3.1, and KCa4, is integral to various cellular functions. It activates a potassium channel in response to calcium, facilitating membrane hyperpolarization and calcium entry. This activity is essential for T-cell activation, proliferation, and EGF-induced macropinocytosis.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Intermediate conductance calcium-activated potassium channel protein 4 could open doors to potential therapeutic strategies. Its direct link to Dehydrated hereditary stomatocytosis 2 highlights its importance in genetic disorders affecting red blood cells, presenting opportunities for targeted therapy development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.